Last reviewed · How we verify
Double dose of PPI
At a glance
| Generic name | Double dose of PPI |
|---|---|
| Sponsor | Mahidol University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Radiofrequency in the Treatment of Barrett's Oesophagus (PHASE4)
- A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis (PHASE3)
- Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection (PHASE4)
- The Mechanism Versus PPI Trial (PHASE4)
- Stop of Proton-pump Inhibitor Treatment in Patients With Liver Cirrhosis - a Double-blind, Placebo-controlled Trial (PHASE4)
- Efficacies of HDDT With or Without Bismuth vs Amoxicillin-metronidazole BQT for First-line H Pylori Eradication (PHASE4)
- Vonoprazan-based Therapy Versus Standard Regimen for Helicobacter Pylori Infection Management (PHASE4)
- Comparison of the Efficacies of Two Novel Dose Dual Therapies in the First-line Helicobacter Pylori Eradication (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Double dose of PPI CI brief — competitive landscape report
- Double dose of PPI updates RSS · CI watch RSS
- Mahidol University portfolio CI